Valeant’s OTC Pickups Emphasize Specialty Segments, Growth Markets
This article was originally published in The Tan Sheet
Executive Summary
The Montreal pharma company includes a focus on OTCs and generics in its quest to grow while remaining relatively immune to patent cliffs and scaled-back Rx reimbursements. Valeant’s recent PEDiNOL Pharmacal acquisition, including OTC podiatry products, fits into its niche category strategy.
You may also be interested in...
European OTC Switch Still Muted By Regulatory Resistance
OTC sales growth is stifled by the EU’s “extremely restricted” switch evaluation process, says AESGP Director General Hubertus Cranz. But while prescription revenues shrink as governments tighten budgets, the OTC market is not hampered in this way.
Valeant Includes OTCs In Bid For Dramatic Growth By 2013
The Ontario-based firm has its sights set on becoming a top-15 pharma company with a $50 billion market capitalization by the end of 2013. Emerging markets and consumer health products, including the recent iNova and Fleming deals, play a big part in Valeant’s plans.
In Brief
Valeant acquires iNova, closes Afexa deal; CRN says FDA’s proposed rule on gifts “goes too far”; Kentucky bill would strengthen PSE limits; and more OTC drug and nutritional product market news In Brief